Sandy Hinckley

I recently came across an incredibly interesting article highlighting a novel application for NK Cell Therapy to treat Alzheimer's using NKGen Biotech, Inc. SNK01 platform. Preliminary data indicate remediation of some of the most debilitating symptoms associated with this disease, likely driven by NK cells' ability to "remove protein aggregates in the brain, while at the same time, reducing neuroinflammation". This is also a testament to the unbound potential cell therapies as we continue to explore and shift the paradigm of what is possible. It will be exciting to see how these data evolve as they progress through clinical trials in the US and Canada. https://lnkd.in/esq7v7WZ #celltherapy #alzheimers #NKcell

28

1 Comment

Allucent helps sponsors navigate the complex NDA & BLA submissions with the FDA! From mastering Pre-NDA/BLA meetings to crafting impactful #FDA meeting packages, we provide the insights needed for a seamless drug approval process. 🚀💼 Want to explore how we can support your next steps? Send me a message, and I'll connect you with our expert Regulatory Strategy team.

14

Come visit us in Boston next week! Empowered with relative affinity analysis as you conduct series of binding / blocking assays on the Beacon, it can be your workhorse for not just difficult antigen, but every-use antigen with much more accelerated pace. Any antigen, any species, most detailed functional screening of antibodies. Antibody discovery. Autoimmune autoantibody discovery. Vaccine development from patient samples. Who doesn’t need a good antibody? Try #Beacon optofluidic technology. Exquisite control, deepest insight.

19

Don't miss our poster presentations at Discovery on Target in Boston, MA! 📃 "Identification and characterization of small molecules inhibiting RNA targets: miRNA" 🏷 Session A, poster A39 📆 October 1st to 2nd a.m. 👩🏼‍🔬 Paola C., PhD, Director Alliance Management Abstract: RNA plays a key role in transcription and translation: gene regulation, proliferation, apoptosis, and development. The biological function is linked to the unique secondary and tertiary structures. Many diseases are associated with dysregulation of RNA functions, so there is a growing interest in RNAs as drug targets for novel therapies or targeting undruggable proteins. The most used modalities are antisense oligonucleotides (ASOs), CRISPR gene editing, and more recently small molecules. [...] Discover more about our approach that demonstrates a miRNA targeting platform that could be applied to other oncogenic miRNA targets: https://lnkd.in/edM4ecJj For more questions and details, come and meet our team at our booth 508! #DrugDiscovery #Biophysics #RNA #SPR #microRNA #DiscoveryOnTarget #BostonDOT24

44